Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies

A review of management approaches to Hodgkin lymphoma in Europe vs the United States/North America demonstrates that although some differences exist, worldwide studies that would enhance patient outcomes are feasible.

Latest News

Long-Term Survival in Patients With Advanced Stage Hodgkin Lymphoma


Researchers analyzed long-term follow-up data from 2 clinical trials conducted by the German Hodgkin Study Group.

5-Azacitidine May Lead to Sustained Response in Peripheral T-Cell Lymphoma


Patients with peripheral T-cell lymphomas have a median overall survival of approximately 6 months.

Conflicting Findings of EBV-Biomarker Use in HIV-Related Lymphomas

By Zahra Masoud

Conflicting findings regarding the association between plasma Epstein-Barr virus load in PLWHIV and HIV-related lymphomas shows a need for assessment of who benefits from an optimal management of HIV infection and comorbidities.

New Assay May Aid Identification of Primary Mediastinal B-Cell Lymphoma


The current approach to PMBCL diagnosis is not optimal due to the possibility of diagnostic inaccuracy.

Symptomatic Osteonecrosis as a Treatment Complication in Hodgkin Lymphoma


Though osteonecrosis has been previously studied in childhood ALL, it has not been evaluated as a side effect of treatment for Hodgkin lymphoma.

Brentuximab Vedotin Combo Active in Older Patients With Hodgkin Lymphoma

By Christina Bennett, MS

Sequential dosing of brentuximab vedotin before and after standard doxorubicin, vinblastine, and dacarbazine showed a survival benefit in a phase II trial.

Pivotal Trial Underway for Zanubrutinib in Waldenström Macroglobulinemia

By Christina Bennett, MS

The safety and efficacy of investigational agent zanubrutinib is being evaluated in a head-to-head phase 3 trial in Waldenström macroglobulinemia.

Two Independent Variables Found to Be Prognostic in Diffuse Large B-Cell Lymphoma

By Randi Hernandez

Baseline ctDNA levels and, separately, measures of molecular response, were prognostic for outcome in patients with diffuse large B-cell lymphoma.

Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin

By James Nam, PharmD

A retrospective study evaluated the efficacy vs pulmonary toxicity of brentuximab vedotin for relapsed or refractory Hodgkin lymphoma in pediatric patients.

Rituximab Maintenance Improved Long-Term Survival in Elderly With Follicular Lymphoma

By James Nam, PharmD

A retrospective analysis of outcomes demonstrated the influence of rituximab maintenance after R-CHOP or R-CVP for follicular lymphoma in elderly patients.

Insurance Status Influences Overall Survival in Follicular Lymphoma

By James Nam, PharmD

Outcomes data demonstrated the impact of socioeconomic status and insurance coverage on outcomes for patients with follicular lymphoma by age (younger than 65 and 65 and older).

Rituximab-Based Immunotherapy May Be As Effective as Chemotherapy in Follicular Lymphoma

By James Nam, PharmD

Rituximab plus lenalidomide immunotherapy may be an effective alternative to chemotherapy for patients with follicular lymphoma.

RiBVD Effective in the First-Line Setting for Mantle Cell Lymphoma

By James Nam, PharmD

Researchers sought to determine if the newly formed regimen RiBVD was effective and tolerable in patients older than 65 with mantle cell lymphoma.

Lenalidomide Plus R-CHOP Effective in High-Burden Follicular Lymphoma

By James Nam, PharmD

A phase 2 study was conducted to determine the effectiveness of adding lenalidomide to R-CHOP as a first-line treatment for high-burden follicular lymphoma.

Ibrutinib Plus Rituximab Granted FDA Approval for Waldenström Macroglobulinemia

By James Nam, PharmD

Rituximab plus ibrutinib is the first nonchemotherapy combination regimen approved in Waldenström macroglobulinemia.

Soluble PD-1 Ligands May Contribute to the Pathogenesis of Waldenström Macroglobulinemia

By Randi Hernandez

New evidence appears to support the potential utility of checkpoint inhibitors in Waldenström macroglobulinemia.

Half-Dose R-CHOP May Be Effective, Reduce Toxicity, in Waldenström Macroglobulinemia

By James Nam, PharmD

Due to its rarity, there is neither robust evidence nor many completed studies supporting specific treatment regimens in Waldenström macroglobulinemia.

FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma

By James Nam, PharmD

Mogamulizumab-kpkc (Poteligeo), a humanized monoclonal antibody that targets CCR4, provides a new treatment option for patients with MF and is the first FDA-approved therapy for SS.

Ibrutinib Monotherapy Effective in CXCR4- and MYD88-Mutated Waldenström Macroglobulinemia

By James Nam, PharmD

The effect of MYD88 and CXCR4 mutations on therapy response among patients with treatment-naïve Waldenström macroglobulinemia requires further investigation.

Waldenström Macroglobulinemia in Europe: Current Practices and Outcomes

By James Nam, PharmD

A better understanding of current practices may lead to improved, standardized care, as well as better use of health care resources in Waldenström macroglobulinemia.